Coagulation abnormalities in acute lung injury and sepsis.
Abraham
E
E
Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA.
D000208:Acute Disease; D000818:Animals; D000990:Antithrombin III / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000209:etiology*; D003167:Complement Activation; D016207:Cytokines / Q000633:toxicity; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy / Q000209:etiology; D019446:Endotoxemia / Q000097:blood / Q000150:complications; D005337:Fibrin / Q000378:metabolism; D005786:Gene Expression Regulation; D006470:Hemorrhage / Q000097:blood / Q000145:classification; D006801:Humans; D008074:Lipoproteins / Q000502:physiology / Q000627:therapeutic use; D055370:Lung Injury; D011323:Primates; D011486:Protein C / Q000627:therapeutic use; D017382:Reactive Oxygen Species; D012128:Respiratory Distress Syndrome / Q000097:blood* / Q000150:complications; D018805:Sepsis / Q000097:blood* / Q000150:complications; D013925:Thromboplastin / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology; D014158:Transcription, Genetic; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects / Q000494:pharmacology / Q000502:physiology
D016207:Cytokines; D008074:Lipoproteins; D011486:Protein C; D017382:Reactive Oxygen Species; D014409:Tumor Necrosis Factor-alpha; C051928:lipoprotein-associated coagulation inhibitor; D000990:Antithrombin III; D005337:Fibrin; D013925:Thromboplastin